What is NasaClip?
NasaClip operates at the intersection of medical technology and patient care, specializing in the development of non-invasive, hands-free devices designed to treat epistaxis, or nosebleeds. The core innovation lies in the application of constant, uninterrupted external nasal pressure, which is further enhanced by the integration of medicated intranasal sponges. This dual-action mechanism is engineered to provide rapid, effective relief, effectively disrupting traditional, often cumbersome, methods of nasal bleeding control.
By focusing on ease of use and clinical efficacy, NasaClip is carving out a distinct niche in the urgent care and home health markets. The company's technology addresses a common yet underserved medical condition, positioning it as a high-potential player in the broader life sciences sector. Its focus on scalable, patient-friendly solutions aligns with current trends toward decentralized healthcare and improved patient outcomes.
How much funding has NasaClip raised?
NasaClip has raised a total of $3.6M across 4 funding rounds:
Other Financing Round
$250K
Other Financing Round
$500K
Other Financing Round
$2.6M
Angel/Pre-Seed
$250K
Other Financing Round (2023): $250K with participation from Tedco
Other Financing Round (2023): $500K led by Tedco
Other Financing Round (2024): $2.6M, investors not publicly disclosed
Angel/Pre-Seed (2025): $250K featuring Tedco
Key Investors in NasaClip
Tedco
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for NasaClip?
With the infusion of this latest capital, NasaClip is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its clinical validation studies. The strategic focus will likely shift toward securing broader regulatory clearances and establishing distribution partnerships that can facilitate entry into both clinical and consumer retail channels.
Furthermore, the company is poised to leverage its intellectual property to explore additional applications for its pressure-based delivery system. As NasaClip transitions into this next phase of growth, the emphasis will remain on operational excellence and market penetration, ensuring that its innovative treatment becomes a standard component of first-aid and emergency medical kits globally. The firm's ability to maintain investor interest throughout its lifecycle suggests a strong foundation for long-term commercial viability.
